Cross-Reactivity Between Heparin and Danaparoid Antibodies in Cardiac Surgery

详细信息    查看全文

• 作者：Thibault Ronchard ; MD ; PharD^a ; Erwan Salaun ; MD^a ; ^b ; Alexis Theron ; MD^a ; Dominique Grisoli ; MD^a ; Nicolas Jaussaud ; MD^a ; Fr&eacute ; d&eacute ; ric Collart ; MD ; PhD^a ; Gilbert Habib ; MD ; PhD^b ; ^d ; Laurence Camoin-Jau ; PharD ; PhD^c ; ^d ; ^{lcamoin@ap-hm.fr}
• 刊名：The Annals of Thoracic Surgery
• 出版年：2017
• 出版时间：January 2017
• 年：2017
• 卷：103
• 期：1
• 页码：e9-e10
• 全文大小：438 K
• 卷排序：103

文摘

Management of heparin-induced thrombocytopenia (HIT) entails cessation of heparin and initiation of a nonheparin parenteral anticoagulant such as danaparoid. Danaparoid cross-reactivity with HIT antibodies is an uncommon complication of treatment of HIT. We report the case of confirmed HIT and in vivo cross-reactivity with danaparoid, complicating severe sepsis due to an infectious endocarditis treated by cardiac surgery.